

## **Adult CIRB - Early Phase Emphasis Meeting Agenda**

**August 17, 2021**

---

### **I Continuing Review**

**10324**, A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum-Resistant or Ineligible Ovarian and Related Cancers with Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC) (Protocol Version Date 06/28/21)

---

### **II Continuing Review**

**10384**, A Phase 1b/2 Study of Hu5F9-G4 (magrolimab) in Combination with Mogamulizumab in Relapsed/Refractory Treated T- cell Lymphoma (Protocol Version Date 12/18/20)

---

### **III Continuing Review**

**ABTC-1801**, Phase I/II Study of Pamiparib (BGB-290) with Temozolomide in Recurrent Gliomas with IDH1/2 Mutations (Protocol Version Date 07/29/20)

---

### **IV New Study ReReview**

**10433**, Phase I/Ib trial evaluating the safety and efficacy of BET inhibitor, ZEN003694 with PD-1 inhibitor, nivolumab with or without CTLA-4 inhibitor, ipilimumab in solid tumors (Protocol Version Date 07/13/21)

---

### **V Amendment**

**10246**, A Phase 1 Study of MLN4924 (pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (Protocol Version Date 07/19/21)

---

### **VI Amendment**

**10398**, A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma (Protocol Version Date 06/22/21)

---